CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,171 | -63.9% | 180 | -67.7% | 0.00% | -60.0% |
| Q2 2023 | $22,643 | 0.0% | 557 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $22,643 | +0.0% | 557 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $22,642 | -29.2% | 557 | 0.0% | 0.01% | -37.5% |
| Q3 2022 | $32,000 | -56.2% | 557 | -41.9% | 0.01% | -55.6% |
| Q2 2022 | $73,000 | +21.7% | 959 | 0.0% | 0.02% | +28.6% |
| Q1 2022 | $60,000 | -97.2% | 959 | -96.6% | 0.01% | -97.2% |
| Q4 2021 | $2,118,000 | -26.6% | 27,943 | +8.4% | 0.51% | -33.5% |
| Q3 2021 | $2,886,000 | -31.4% | 25,782 | -0.8% | 0.76% | -31.1% |
| Q2 2021 | $4,208,000 | +39.1% | 25,992 | +4.7% | 1.10% | +26.5% |
| Q1 2021 | $3,026,000 | -21.7% | 24,833 | -1.6% | 0.87% | -28.9% |
| Q4 2020 | $3,863,000 | +89.1% | 25,229 | +3.3% | 1.23% | +207.5% |
| Q3 2020 | $2,043,000 | -4.6% | 24,428 | -16.2% | 0.40% | -50.7% |
| Q2 2020 | $2,141,000 | +4360.4% | 29,149 | +2468.2% | 0.81% | +3421.7% |
| Q1 2020 | $48,000 | -36.0% | 1,135 | -8.1% | 0.02% | -23.3% |
| Q4 2019 | $75,000 | +47.1% | 1,235 | 0.0% | 0.03% | +76.5% |
| Q3 2019 | $51,000 | – | 1,235 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |